GlassScriptPhysician profile
Brian S Christine
NPI 1982677142
$214,861.88
in general payments reported to CMS, 2019-2025
23 companies · $4,437 in 2025
The $4,437 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $24K · 2021: $25K · 2022: $5,293 · 2023: $9,415 · 2024: $48K · 2025: $4,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $13K · Travel and Lodging: $5,245 · Food and Beverage: $3,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,745.00 |
| Consulting Fee | $12,940.00 |
| Travel and Lodging | $5,245.06 |
| Food and Beverage | $3,864.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $199,487.55 | 2019-2025 | Advance Xp, Ams 800 Artificial Urinary Sphincter, Ams 700 Cxr Rte Kit |
| Coloplast Corp | $13,288.75 | 2019-2024 | Titan, Saffron |
| Endo Pharmaceuticals INC. | $539.36 | 2020-2024 | Xiaflex, Aveed |
| Abbvie INC. | $320.89 | 2020-2024 | Botox |
| Endo USA, INC. | $221.46 | 2024-2025 | Xiaflex |
| Laborie Medical Technologies Corp. | $125.00 | 2023 | |
| Sumitomo Pharma America, INC. | $119.68 | 2023-2025 | Gemtesa |
| Allergan, INC. | $105.75 | 2020 | |
| Antares Pharma, INC. | $101.89 | 2020-2023 | Nocdurna, Tlando, Xyosted |
| Astellas Pharma US INC | $94.07 | 2019-2024 | Myrbetriq, Veozah |
| Procept Biorobotics Corporation | $70.04 | 2024 | Aquabeam System |
| Medtronic, INC. | $64.86 | 2021-2023 | Interstim |
| Tolmar, INC. | $55.70 | 2023 | |
| Halozyme INC | $46.63 | 2023 | |
| Urovant Sciences INC | $45.72 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $39.98 | 2021-2025 | Prolaris |
| Rigicon,INC. | $31.48 | 2022 | |
| Axonics, INC. | $26.33 | 2022-2023 | Axonics |
| Tolmar Pharmaceuticals, INC. | $22.11 | 2022 | |
| Blue Earth Diagnostics | $20.16 | 2023 | |
| Amgen INC. | $13.45 | 2019 | |
| Travere Therapeutics, INC. | $12.77 | 2019-2020 | |
| Ambu INC. | $8.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Christine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.